Company intelligence / Profile preview

Betagenon

Umeå, Västerbottens län, Swedenamplifier-tx.com ↗

Ownership: Private
Employees: ~24
Development stage: Phase 1

Overview

Betagenon develops small molecule compounds that activate AMP‑activated protein kinase (AMPK), targeting metabolic, cardiorenal, and inflammatory diseases. The company has received EU Horizon 2020 funding for its research and has demonstrated preclinical and early clinical progress with its AMPK activator programs. Detailed clinical results are not publicly available.

Therapeutic areas: Metabolic DisordersCardiovascularImmunology
Modalities: Small molecules (AMPK activators)
Industry: Biotech

Drug pipeline

1 asset

ATX-304

Phase 1

Indications: Cardiometabolic diseases, Heart failure with preserved ejection fraction

Partnerships

Received funding from EU’s Horizon 2020 research program; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on Betagenon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Betagenon.

Explore the full profile